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Abstract
Background: Microglial-mediated neuroinflammation is a key factor underlying the pathogenesis of various
neurodegenerative diseases and also an important target for the development of the neuroinflammation-targeted
therapeutics. Conventionally, the nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed, but they are associated
with long-term potential risks. Natural products are the cornerstone of modern therapeutics, and Ashwagandha is one
such plant which is well known for its immunomodulatory properties in Ayurveda.
Methods: The current study was aimed to investigate the anti-neuroinflammatory potential of Ashwagandha (Withania
somnifera) leaf water extract (ASH-WEX) and one of its active chloroform fraction (fraction IV (FIV)) using β-amyloid and
lipopolysaccharide (LPS)-stimulated primary microglial cells and BV-2 microglial cell line. Iba-1 and α-tubulin
immunocytochemistry was done to study the LPS- and β-amyloid-induced morphological changes in microglial
cells. Inflammatory molecules (NFkB, AP1), oxidative stress proteins (HSP 70, mortalin), apoptotic markers (Bcl-xl,
PARP), cell cycle regulatory proteins (PCNA, Cyclin D1), and MHC II expression were analyzed by Western
blotting. Mitotracker and CellRox Staining, Sandwich ELISA, and Gelatin Zymography were done to investigate
ROS, pro-inflammatory cytokines, and matrix metalloproteinase production, respectively. Ashwagandha effect
on microglial proliferation, migration, and its apoptosis-inducing potential was studied by cell cycle analysis,
migration assay, and Annexin-V FITC assay, respectively.
Results: ASH-WEX and FIV pretreatment was seen to suppress the proliferation of activated microglia by causing
cell cycle arrest at Go/G1 and G2/M phase along with decrease in cell cycle regulatory protein expression such as
PCNA and Cyclin D1. Inhibition of microglial activation was revealed by their morphology and downregulated
expression of microglial activation markers like MHC II and Iba-1. Both the extracts attenuated the TNF-α, IL-1β, IL-6, RNS,
and ROS production via downregulating the expression of inflammatory proteins like NFkB and AP1. ASH-WEX and FIV
also restricted the migration of activated microglia by downregulating metalloproteinase expression. Controlled
proliferation rate was also accompanied by apoptosis of activated microglia. ASH-WEX and FIV were screened and
found to possess Withaferin A and Withanone as active phytochemicals.
Conclusions: The current data suggests that ASH-WEX and FIV inhibit microglial activation and migration and
may prove to be a potential therapeutic candidate for the suppression of neuroinflammation in the treatment of
neurodegenerative diseases.
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Background
Neuroinflammation accompanies all neurological afflictions
from traumatic brain injuries and nervous system infections
to chronic neurodegenerative diseases. Microglia, resident
immune cells in the brain, are the key contributors of this
neuroinflammation resulting in neurodegeneration. The
microglial-mediated neuroinflammation has been the char-
acteristic diagnostic feature of various neurodegenerative
diseases, including Alzheimer’s disease (AD), Parkinson’s
disease (PD), trauma, multiple sclerosis (MS), and cerebral
ischemia [1]. Under normal physiological conditions, these
special brain macrophages serve the role of immune
surveillance displaying M2 phenotype by secreting various
neurotrophic and anti-inflammatory factors creating pro-
tective microenvironment for the neurons. However, in
response to infection or injury, they readily become acti-
vated and converted in the form of M1 phenotype display-
ing a variety of surface receptors, including the MHCs and
complement receptors [2]. They also undergo dramatic
morphological changes from resting ramified cells to
activated amoeboid microglia [3]. Chronic activation of
microglia results in neuroinflammation by secreting various
neurotoxic and pro-inflammatory mediators causing
demyelination and neuronal death [4]. These mediators
include PGE2, monocyte chemoattractant protein-1
(MCP-1), inflammatory cytokines such as interleukin-1
β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α)
and free radicals such as nitric oxide (NO) and superoxide,
fatty acid metabolites such as eicosanoids, and quinolinic
acid [5].
Conventionally, various nonsteroidal anti-inflammatory
drugs (NSAIDs) like rofecoxib, COX 2 inhibitors, aspirin,
mefenamic acid, indomethacin, and ketoprofen are used
to treat neurodegenerative diseases [6, 7]. However, treat-
ment with NSAIDs is generally accompanied by various
side effects like gastrointestinal problems, dizziness, head-
ache, and dyspepsia as their major drawback. Recently,
many medicinal herbs and their bioactive components like
epigallocatechin-3-gallate (EGCG) from Camellia sinensis,
curcumin from Cucurma longa, and resveratrol from
grapes have been reported to possess anti-inflammatory
activity and are more safe, effective, and easy to use than
the NSAIDs with negligible potential risks [8–11].
Withania somnifera is the most popular medicinal
plant in Ayurveda for its nerve tonic and memory enhan-
cing properties. It is also well acknowledged for its longev-
ity and vitality increasing properties [12]. Ashwagandha has
been reported to possess a number of therapeutic prop-
erties including anti-inflammatory, sedative, hypnotic,
narcotic, and general tonic [13]. The root extract of
Withania has been found to be effective in protecting
against hydrogen peroxide- and β-amyloid (1–42)-in-
duced cytotoxicity in NGF-differentiated PC12 cells
[14]. Withania contains active ingredients like steroidal
alkaloids and lactones known as “withanolides.” Among the
bioactive components of Withania, Withaferin A (Wit A)
and withanolide D are well characterized which contribute
to the most of the pharmaceutical properties of this plant
[15]. Wit A has been shown to exhibit anti-inflammatory
acitivity via NF-kB activation inhibition by blocking IkB
phosphorylation and inhibiting IkB kinase activation
[16, 17]. It also inhibited lipopolysaccharide (LPS)-induced
PGE2 production and COX-2 expression in BV-2 cells and
primary microglia, and these effects are mediated, at least
in part, by reduced phosphorylation and nuclear transloca-
tion of STAT1 [18].
The anticancerous activity of Ashwagandha has already
been well documented by our lab using both in vitro and
in vivo model systems [19–21]. Further, it has also been
shown to have neuroprotective potential against glutamate
cytotoxicity [22].
In view of the previous reports, the present study was
planned to further elucidate anti-neuroinflammatory po-
tential of Ashwagandha leaf water extract (ASH-WEX)
and one of its active chloroform fraction (fraction IV
(FIV)) in LPS-induced primary microglial cells and BV-2
murine microglial cell line as an in vitro model system.
LPS-induced activation of the microglial cells is a useful
model for the study of neuroinflammation and nerve cell
injury as they release various pro-inflammatory and
neurotoxic factors [23]. We have also done preliminary
study using β-amyloid-activated BV-2 and primary micro-
glial cells as the inflammatory model to confirm the anti-
neuroinflammatory potential of ASH-WEX and FIV in
alternative condition. β-amyloid both recruits and activates
the microglia, thereby initiating vicious cycle of the in-
flammation between β-amyloid accumulation, activated
microglia and microglial inflammatory mediators, which
enhance β-amyloid deposition and neuroinflammation
thus considered as the unifying factor in the development
of AD [24]. Further, we examined the signaling cascades
associated with ASH-WEX and FIV on the proliferation
and migration of LPS-induced microglial cells and their
phenotypic changes which have been found to be respon-
sible for neuronal damage in various neurological disor-
ders. We further studied the effect of ASH-WEX and FIV
on various inflammatory pathways like nuclear factor-kB
(NFkB), activator protein 1 (AP1), and pAktSER-473 which
are known to mediate the production of various pro-
inflammatory mediators like reactive nitrogen species
(RNS), reactive oxygen species (ROS), inflammatory
cytokines, and matrix metalloproteinases (MMPs) as a
result of microglial cell activation.
Methods
Ashwagandha leaf extract
The ASH-WEX was prepared by suspending 10 g of dry
leaf powder of Ashwagandha in 100 ml of water and
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stirring it overnight at 45 °C in shaker incubator. The
suspension was then filtered under sterile conditions to
obtain the aqueous leaf extract. The filtrate obtained was
treated as 100 % aqueous extract and diluted in Dulbecco’s
modified Eagle’s medium (DMEM) with 10 % fetal bovine
serum (FBS) according to experimental requirement.
One of its fractions was prepared by solvent extraction
in the following order: hexane→ chloroform→ ethylace-
tate→ butanol. Then, the active chloroform fraction was
further fractionated by thin-layer chromatography using
hexane: ethylacetate as the mobile phase and four frac-
tions were obtained. Out of these, one fraction was active
in suppressing LPS-induced microglial activation and was
labeled as the FIV. It was then dried and dissolved in
DMSO at the concentration of the 50 mg/ml and diluted
in DMEM according to the experimental requirement.
ASH-WEX and FIV were also analyzed for the presence
of the possible bioactive components Wit A and Witha-
none by reverse-phase chromatography. For HPLC, the
samples were prepared by dissolving dried ASH-WEX and
FIV in methanol at 10 and 2 mg/ml concentration, re-
spectively. Purified Wit A and Withanone dissolved in
methanol were used as the standards to determine
their concentration in ASH-WEX and FIV.
Primary microglial cultures
Primary microglia-enriched cultures were obtained from pri-
mary mixed glial cultures from 1-day-old Wistar rat pups.
Animal care and procedures were followed in accordance
with the guidelines of the Animal Ethical Committee, Guru
Nanak Dev University, Amritsar, India. To obtain mixed
glial cultures, the brain was dissected; their meninges were
carefully removed and digested with 0.05 % trypsin-EDTA
solution for 10 min at 37 °C. Trypsinization was stopped by
adding an equal volume of DMEM culture medium supple-
mented with 10 % FBS. Cells were pelleted (5 min, 200 g),
resuspended in culture medium, and brought to a single-cell
suspension by repeated pipetting. Cells were seeded and cul-
tured at 37 °C in a 5 % CO2 humidified atmosphere.
Medium was replaced after every 3 days. Microglial cultures
were prepared by the mild trypsinization method [25].
Briefly, after 18–20 days, in vitro (DIV) mixed glial cultures
were treated for 30 min with 0.25 % trypsin containing
1 mM EDTA diluted with DMEM containing 1 mM Ca2+
in 1:3 ratio. This resulted in the detachment of an intact
layer of cells containing virtually all the astrocytes, leaving a
population of firmly attached cells identified as 98 % micro-
glia. Isolated microglial cells were seeded in multiwell plates
by trypsinization with 0.25 % trypsin-EDTA for 10 min and
treated after 24 h of seeding.
BV-2 cell culture and treatments
BV-2 cell line was obtained from National Brain Research
Centre (NBRC), Manesar, Haryana, India. BV-2 cells are
murine-cultured microglial cells immortalized after trans-
fection with a v-raf/v-myc recombinant retrovirus. The cells
were maintained in DMEM medium with 10 % FBS
(Biological Industries) and 1× PSN mix (Invitrogen,
Carlsbad, CA, USA) at 37 °C in 5 % CO2 and humid
environment.
Both primary and BV-2 microglial cultures were pre-
treated with ASH-WEX and FIV for 2 h before adding
100 ng/ml LPS to cultures (LPS (rough strains) from
Escherichia coli F583 (Rd mutant) and 5 nM β-amyloid
(Sigma-Aldrich, Saint Louis, Missouri, 63103 USA).
Treatment was done for 36 h before harvesting for dif-
ferent assays.
Cytotoxicity and cell viability assays
ASH-WEX and one of its active fraction (FIV) were
tested for cell viability using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. The
cell viability was quantified by the conversion of yellow
MTT by mitochondrial dehydrogenases of living cells to
purple MTT formazan at 595-nm wavelength [26].
Cell morphology studies
Morphological changes in both primary and BV-2
microglial cells treated with different concentrations
of ASH-WEX and FIV with or without activation with
LPS and β-amyloid were studied by phase contrast micros-
copy. These experiments were performed in 24-well plates
containing poly-L-lysine-coated coverslips (20,000 cells/ml).
The phase contrast images of culture were taken using
Phase Contrast Inverted Microscope (Nikon TE2000). Nu-
clear morphology was studied by staining the nucleus with
an AT-rich region-specific fluorescent stain, i.e., 4′,6-diami-
dino-2-phenylindole (DAPI).
Immunostaining
Both primary and BV-2 microglial cells, control and
treated, were washed with 1× phosphate-buffered saline
(PBS) thrice and were fixed with acetone to methanol
followed by permeabilization with 0.3 % Triton X-100 in
PBS (PBST). Cells were then incubated with anti-α-tubulin
(1:500) or anti-NF-kB (1:300) or anti-AP1 (1:300) or anti-
HSP-70 (1:300) (from Sigma-Aldrich) diluted in 2 % BSA,
for 24 h at 4 °C in humid chamber. After two to three
washings with 0.1 % PBST, the cells were incubated with
the secondary antibody anti-mouse IgG 488 and anti-rabbit
IgG 488 (prepared in 2 % BSA (1:500)) for 2 h at room
temperature. Cells were incubated with (DAPI, 1:5000 in
1× PBS) for 10 min for nuclear staining and then mounted
with anti-fading reagent (Fluoromount, Sigma). For CellRox
and Mitotracker staining, after treatment period, the dye
was added in culture according to the manufacturer’s in-
structions; cells were then fixed and mounted. Images were
captured using Nikon AIR Confocal Laser Microscope and
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analyzed using NIS elements AR analysis software version
4.11.00. Experiment was performed in triplicate.
Protein assay and Western blotting
For total protein extraction, BV-2 microglial cells were
grown and treated in 100-mm petri dishes followed by
harvesting with PBS-EDTA (1 mM). Nuclear and cyto-
plasmic protein fractionation was performed using a
CelLytic NuCLEAR extraction kit from Sigma-Aldrich.
Briefly, the cell pellet obtained was allowed to swell with
hypotonic buffer (100 mM HEPES, pH 7.9, 15 mM
MgCl2, and 100 mM KCl). To the swollen cells in lysis
buffer, 10 % IGEPAL CA-630 solution was added to a
final concentration of 0.6 % and vortexed vigorously for
10 s. The cells are then disrupted, the cytoplasmic fraction
was removed, and the nuclear proteins were released from
the nuclei by a high-salt buffer (20 mM HEPES, pH 7.9,
with 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, and
25 % (v/v) glycerol). For total protein extraction, the cell
pellet was homogenized in RIPA buffer (50 mM Tris (pH
7.5), 150 mM NaCl, 0.5 % sodium deoxycholate, 0.1 %
sodium dodecyl sulfate (SDS), 1.0 % NP-40). Protein con-
centration was determined by the Bradford method. Protein
lysate (30–50 μg) was resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), followed by transfer onto a
PVDF membrane (Hybond-P) using the semi-dry Novablot
system (Amersham Pharmacia). Further, membranes were
probed with anti-mortalin (1:1000), anti-HSP70 (1:2500),
anti-NFkB (1:2500), anti-OX-42 (1:1000), anti-OX-6
(1:1000), anti-PARP (1:1500), anti-Bcl-xl (1:1000),
anti-AP1 (1:2500), anti-Akt (1:2500), and anti-Cyclin
D1 (1:2000) (Sigma-Aldrich) and anti-proliferating cell
nuclear antigen (PCNA) (1:2000) (Chemicon International,
Temecula, CA, USA), for overnight at 4 °C. This was
followed by washing with 0.1 % TBST and incubation with
HRP-labeled secondary antibodies for 2 h at room
temperature. Immunoreactive bands were detected by
ECL Plus Western blot detection system (Amersham
Biosciences) using LAS 4000 (GE Biosciences). α-
Tubulin has been used as an endogenous control for
normalizing the expression of the protein of interest. α-
Tubulin and histone 3 were used as internal control for
cytoplasmic and nuclear expression of proteins of inter-
est, respectively. The change in expression of gene of
interests was taken on the average of IDV values ob-
tained from at least three independent experiments.
Cell cycle analysis
BV-2 microglial cells were seeded at the cell density
2.5 × 105 per ml in 100-mm-diameter petri plates and
then treated according to the regime for 36 h. Cells from
four petri dishes were pooled together. After 36 h of
treatment, cells were trypsinized and then centrifuged at
1000 rpm. The cell pellet was resuspended in 1 ml of
ice-cold PBS and then fixed with ice-cold 70 % ethanol
for 2 h at 4 °C. Cells were then centrifuged and resus-
pended in 1 ml of PBS and incubated for 15 min and again
centrifuged and resuspended in propidium iodide (PI)
staining solution (100 mM Tris pH 7.4, 150 mM CaCl2,
0.5 mM MgCl2, 0.1 % NP-40, and 3 μM PI) and scanned
with BD Accuri C6 Flow cytometer (BD Biosciences). DNA
content histograms and cell cycle phase distribution were
analyzed from at least 50,000 single events by excluding cell
aggregates based on scatter plots of fluorescence pulse area
versus fluorescence pulse width using FCS Express 4 flow
research edition software (De Novo software).
Annexin V-FITC (apoptosis) assay
To further explore whether ASH-WEX and FIV caused the
apoptosis of the activated BV-2 microglia, cell suspension
was harvested from cells grown and treated in 100 mm pet-
ris. Cells from the four petri dishes were pooled together.
Cells were stained with Annexin V conjugated with FITC
and PI using Annexin V-FITC Apoptosis Detection Kit
(Miltenyi Biotech, San Diego, CA, USA). Briefly, 1 ml of 1×
binding buffer was added to cells, and pellet was obtained
after centrifugation at 5000 rpm. One hundred microliters
of 1× binding buffer and 10 μl Annexin V-FITC was added
to it and incubated for 15 min in the dark. Pellet was
obtained by centrifugation at 5000 rpm after adding
1 ml 1× binding buffer and resuspended in 500 μl of 1×
binding buffer. Five microliters of propidine iodide so-
lution was added immediately prior to analysis by BD
C6 Accuri flow cytometer.
Wound scratch assay
In order to test anti-migration potential of ASH-WEX
and FIV, BV-2 microglial cells were grown to confluent
monolayer and then wounded by scratching the surface
with a pipette tip. Cells were firstly pretreated with the
ASH-WEX and FIV followed by activation with LPS.
The initial wounding and the migration of cells in the
scratched area were photographically monitored for
12–24 h after the treatment. Images were analyzed by
Image Pro Plus software version 4.5.1 from the media
cybernetics for the migration of cells in the scratched
area by calculating the distance covered by the invad-
ing cells after incubation. Experiment was repeated for
at least three times in triplicate.
Gelatin zymogram study
In order to study the effect of ASH-WEX and FIV on
matrix metalloproteinase (MMP 2, MMP 9)-conditioned
media from both primary and BV-2 microglial cell cul-
tures after treatment were separated on a 10 % SDS-
PAGE containing 0.1 % gelatin. After electrophoresis,
gels were washed with renaturation buffer (Invitrogen)
for 1 h to remove SDS. The gel was then incubated in
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zymogram developing buffer (Invitrogen) at 37 °C for
48 h followed by staining with Coomassie brilliant blue
and destaining in buffer containing 50 % methanol and
10 % acetic acid (v/v). The location of gelatinolytic activity
was detected as clear white bands.
Nitrite determination
Both primary and BV-2 microglial cells were seeded and
treated as per the regimen. Nitrite determination was
done using the Griess reagent nitrite determination kit
(Molecular Probes, Invitrogen) as per the manufacturer’s
protocol. Briefly, the culture conditioned media was
collected and mixed with the Griess reagent, and the
readings were obtained at the 548-nm wavelength. The
nitrite concentrations were calculated using the sodium
nitrite standard curve.
Pro-inflammatory cytokine assay
Cell culture conditioned media was collected from the
different treatment conditions and analyzed for the pres-
ence of the pro-inflammatory cytokines (IL-1β, IL-6,
TNF-α) using the pro-inflammatory cytokine sandwich
ELISA-based kits (from Sigma-Aldrich).
Statistical analysis
Values are expressed as mean ± standard error of the
mean (SEM) obtained from at least three independent
experiments. The Sigma Stat for Windows (version 3.5)
was used to analyze the results by one-way ANOVA
(Holm-Sidak post hoc method), in order to determine
the significance of the mean values. Values of p < 0.05
were considered as statistically significant.
Results
Standardization of ASH-WEX and FIV effective
concentration
To determine the effective dose of ASH-WEX and FIV,
BV-2 microglial cells were treated with different concen-
trations of ASH-WEX (0.1–2 %) and FIV (5–15 μg/ml)
for 48 h and the cell viability was quantified by the con-
version of yellow MTT into formazan crystals. The IC50
value for ASH-WEX and FIV was at 0.5 % and 15 μg/ml,
respectively (Fig. 1A, i, ii; p ≤ 0.05). On the basis of this
preliminary data, maximum nontoxic doses, i.e., 0.2 %
and 10 μg/ml were used for ASH-WEX and FIV, re-
spectively, for further experiments.
Both β-amyloid and LPS were used as the inflammatory
triggers to activate the microglial cells. To determine their
effective concentration, BV-2 microglial cells were treated
with different concentrations of the β-amyloid (1–
1000 nM) and LPS (0.01–10 μg/ml) for 48 h and immu-
nostained for the cytoskeletal protein α-tubulin. On the
basis of data obtained, 5 nM and 0.1 μg/ml were used
as the effective noncytotoxic concentrations of β-amyloid
and LPS, respectively, to activate the microglial cells.
Effect of ASH-WEX and FIV on the morphology of the
BV-2 microglial cells
Phase contrast images (Fig. 1B, row a, d) of both primary
and BV-2 microglial cells showed significant change in
morphology after 100 ng/ml LPS and 5 nM β-amyloid
treatment. While treatment of BV-2 and primary micro-
glial cells with either ASH-WEX or FIV did not induce
any changes in their morphology, however, treatment of
both ASH-WEX and FIV to LPS- and β-amyloid-exposed
culture group inhibited activation of the microglia as was
seen by normal morphology of these cells. Morphological
changes in LPS- and β-amyloid-induced BV-2 cells were
further confirmed by immunostaining for cytoskeletal pro-
tein α-tubulin, which further clearly showed that activated
microglial cells had amoeboid morphology with thick pro-
cesses and enlarged cell soma. ASH-WEX and FIV pre-
treatment prevented changes in morphology induced by
LPS and β-amyloid in these cells which showed morph-
ology similar to untreated cells (Fig. 1B, row b). We
further confirmed the LPS- and β-amyloid-induced activa-
tion of the BV-2 and primary microglia at molecular level
by studying expression of Iba-1 which is an ionized
calcium-binding adaptor protein specifically expressed in
the microglial cells in the brain. Among the different
groups, LPS and β-amyloid treated both primary micro-
glial cells and BV-2 microglial cells showed maximum ex-
pression of Iba-1 which was suppressed by pretreatment
of these cells by ASH-WEX and FIV (Figs. 1B, row c; 3A,
row a; 1a, iii; p ≤ 0.05) and more pronounced suppression
was observed in FIV-treated group. Since ASH-WEX
and FIV inhibited both LPS and β-amyloid, induced
microglial-mediated neuroinflammation and activation
seen in LPS-treated cultures were more prominent than
the β-amyloid-treated cultures, so we further studied the
expression of the various inflammatory mediators using
LPS-stimulated primary microglial cells and BV-2 cell line.
ASH-WEX and FIV inhibited the LPS-induced inflammatory
pathway proteins
As the change in the cellular morphology is associated
with the functional activity of the microglial cells, we
further studied the expression of various proteins associ-
ated with LPS-induced inflammatory pathways. Immuno-
staining for NFkB and AP1 showed enhanced expression
of these proteins with higher nuclear translocation in
LPS-treated primary microglial cells as compared to con-
trol. However, both ASH-WEX and FIV pretreatment to
these cells downregulated the expression of these mole-
cules and also their translocation to nucleus as depicted
by the confocal images (Fig. 2A, row a and b) and their in-
tensity plots (Fig. 2B, i, ii). Similarly, ASH-WEX and FIV
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also inhibited the expression of NFkB and AP1 in LPS-
stimulated BV-2 microglial cells (Fig. 3A, row b and c).
Immunostaining data was further confirmed by Western
blot analysis of nuclear and cytoplasmic fractions of con-
trol and treated BV-2 microglial cultures which showed
downregulation in nuclear expression of the NFkB and
AP1 in ASH-WEX- and FIV-pretreated groups as com-
pared to LPS alone (Fig. 3B, i, ii, iii). As microglial cells are
key player in the immune response, we studied the expres-
sion of the major histocompatibility complex II (MHC II)
as detected by OX-6 antibody. ASH-WEX- and FIV-
pretreated BV-2 cells showed downregulated expression
of the MHC II as compared to LPS alone treated cells
(Fig. 3B, iv, v) indicating their role in the suppression of
the microglial activation. PI3k-Akt pathway also plays an
important role in inflammation and microglial activation.
Western blot analysis showed that ASH-WEX and FIV
pretreatment significantly downregulated the expression
of pAktSER-473 in these microglial cells as compared to
LPS alone treatment group (p ≤ 0.05; Fig. 3B, iv, v).
ASH-WEX and FIV inhibited the production of the various
pro-inflammatory mediators
Activation of the microglial cells is generally accompanied
by enhanced production of the iNOS which is responsible
for further release of RNS. Thus, we further studied the
Fig. 1 ASH-WEX and FIV pretreatment inhibits both β-amyloid and LPS-induced morphological changes in primary and BV-2 microglia. A Histograms
represent the cytotoxicity assay of the BV-2 microglia treated with the (i) ASH-WEX and (ii) FIV after 48 h of the treatment. ASH-WEX and FIV inhibit the
change in the microglial morphology from ramified to amoeboid due to LPS and β-amyloid treatment. iii Histogram represents the relative optical
intensity of Iba-1 in primary microglial cells among the different treated groups. B (a) Represents the differential interference contrast (DIC) images of
BV-2 microglial cells pretreated with ASH-WEX and FIV with or without treatment with LPS and β-amyloid, (b) Confocal images of α-tubulin
immunostaining of the BV-2 microglia pretreated with ASH-WEX and FIV with or without activation with LPS and β-amyloid showing changes in the
morphology, (c) Confocal images of Iba-1 immunostaining of primary microglial cells pretreated with ASH-WEX and FIV with or without treatment with
LPS and β-amyloid, a specific microglial marker allowing distinction between activated and resting microglia in primary microglial cells, and (d) DIC
images of primary microglial cells pretreated with ASH-WEX and FIV with or without treatment with LPS and β-amyloid (scale bar 50 μm). *p <
0.05 represents statistically significant difference between control and treated groups in MTT assay. *p < 0.05 represents statistically significant
difference between control and β-amyloid + ASH-WEX, β-amyloid + FIV, LPS + ASH-WEX, and LPS + FIV-treated groups. +p < 0.05 represents
statistically significant difference between control and β-amyloid and LPS-treated group. #p < 0.05 represents statistically significant difference
between β-amyloid and β-amyloid + ASH-WEX, β-amyloid + FIV, LPS and LPS + ASH-WEX, and LPS + FIV-treated groups
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RNS levels in control and ASH-WEX- and FIV-pretreated
LPS groups using BV-2 and primary microglial cells. NO
production was assayed by the Griess reagent. This reagent
works on principle of azo coupling between diazonium spe-
cies, which are produced from sulfanilamide in presence of
NO2 and naphthylethylenediamine. ASH-WEX and FIV
were found to inhibit the production of NO significantly in
both primary (by 58 and 78 %, respectively) and BV-2
microglial cells (by 59 and 67 %, respectively), as compared
to LPS-treated group (Figs. 2C, i and 3C, i; p ≤ 0.05). Acti-
vated microglia also produce various pro-inflammatory cy-
tokines which ultimately lead to neuronal damage directly
or indirectly. We detected amount of released inflammatory
cytokines in conditioned media from all the treatment and
control groups. ELISA test showed the highest production
of inflammatory cytokines such as TNF-α, IL-1β, and IL-6
in LPS-treated BV-2 microglial cultures (17, 31, and 15 %
more TNF-α, IL-1β, and IL-6, respectively, as compared to
control). However, this LPS-induced production of inflam-
matory cytokines was significantly inhibited by ASH-WEX
(up to 7 % TNF-α, 45 % IL-1β, 28 % IL-6) and FIV (up to
9 % TNF-α, 40 % IL-1β, 69 % IL-6) pretreatment as com-
pared to LPS alone treated group (Fig. 3C, ii; p ≤ 0.05).
These pro-inflammatory cytokines act as both primary as
well as secondary mediators of neuroinflammation.
In the developing brain, during microglia-mediated in-
flammatory response, expression of the MMPs particularly
gelatinases is concomitantly increased. To determine the
production of MMPs, conditioned media from all the ex-
perimental groups were resolved in 10 % SDS-PAGE con-
taining 0.1 % gelatine. ASH-WEX and FIV significantly
inhibited LPS-induced release of the gelatinases MMP-9
and MMP-2 in both primary and BV-2 microglial cells as
depicted by the gelatin zymogram data (Figs. 2C, ii and
3C, iii; p ≤ 0.05).
ASH-WEX and FIV inhibited the release of the ROS
Since reactive oxygen and nitrogen species act as the
critical signaling molecules to trigger the microglial-
mediated inflammatory responses, thus, the levels of the
ROS production were tested in all control and treatment
groups using CellROX dye whose change in fluorescent
Fig. 2 Inhibitory effects of ASH-WEX and FIV on LPS-induced inflammatory mediators’ expression in primary microglia. A Representative confocal
images of activated primary microglial cells with or without pretreatment with ASH-WEX and FIV immunostained with (a) NFkB and (b) AP1. B i, ii
Histograms represent the relative optical intensities of NFkB and AP1, respectively, in different treated groups as compared to control. C i Represents
the relative production of the nitrite in different treated groups as compared to control due to neuroinflammation as estimated by the Griess reagent.
C ii Representative MMP zymograms for control and different treated groups and histograms represent densitometric analysis of MMP bands. *p < 0.05
represents statistically significant difference between control and LPS + ASH-WEX and LPS + FIV-treated groups. +p < 0.05 represents statistically
significant difference between control and LPS-treated group. #p < 0.05 represents statistically significant difference between LPS and LPS + ASH-WEX
and LPS + FIV-treated groups
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intensity is the indicator of ROS production. ASH-WEX-
and FIV-pretreated primary and BV-2 microglial cells
showed lower red fluorescent intensity as compared to
LPS alone treated cells which clearly indicates that pre-
treatment with ASH-WEX and FIV suppressed LPS-
induced ROS production (Figs. 4A, row a; 5A, row a). As
the main source of cellular ROS production is mitochon-
drial dysfunction, we further examined the effect of the
microglial activation on mitochondrial activity using Mito-
tracker Green FM dye. The change in intensity of this dye
indicates alteration in mitochondrial activity. LPS alone
treated primary and BV-2 microglial cells showed higher
mitochondrial stress as indicated by the highest fluores-
cence level in these cells. However, both ASH-WEX- and
FIV-pretreated cultures showed reduced dye fluorescence
indicating normal mitochondrial activity which may be
Fig. 3 ASH-WEX and FIV pretreatment inhibits LPS-induced various inflammatory pathway protein expression in BV-2 microglia. A Representative
confocal images of activated BV-2 microglial cells with or without pretreatment with ASH-WEX and FIV immunostained with (a) Iba-1, (b) NFkB, and (c)
AP1. B i Representative Western blots of NFkB and AP1 showing inhibition of the translocation of the NFkB from cytoplasm to nucleus and decrease in
expression of AP1 with ASH-WEX and FIV pretreatment. B, iii, iv Representative histograms present normalized relative expression of NFkB
and AP1 plotted as mean ± SEM calculated from three independent experiments. Cytoplasmic expression of protein was normalized with
α-tubulin, and nuclear expression was normalized with histone-3. B ii Representative Western blots of pAkt, OX-6 showing decrease in
expression of pAkt, OX-6 with ASH-WEX and FIV pretreatment. B v Histogram representing mean of densitometric analysis of Western blot
signals of pAkt, OX-6 after normalization with α-tubulin. C ASH-WEX and FIV inhibit the release of the inflammatory mediators due to neuroinflammation
induced by LPS treatment. C i Represents the relative production of the nitrite in different treated groups as compared to control due to neuroinflamma-
tion as estimated by the Griess reagent. C ii Represents histograms depicting the decreased levels of the inflammatory cytokines (TNF-α, IL-1β, IL 6) by the
ASH-WEX and FIV treatment as estimated by Sandwich ELISA. C iii Representative MMP zymograms for control and different treated groups
and histograms represent densitometric analysis of MMP bands. *p < 0.05 represents statistically significant difference between control and
LPS + ASH-WEX and LPS + FIV-treated groups. +p< 0.05 represents statistically significant difference between control and LPS-treated group. #p< 0.05
represents statistically significant difference between LPS and LPS + ASH-WEX and LPS + FIV-treated groups
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the result of attenuated production of ROS (Figs. 4A, row
b; 5A, row b). ASH-WEX and FIV pretreatment also up-
regulated the expression of stress chaperone HSP 70 in
both primary (Fig. 4A, row c, B) and BV-2 microglia
(Fig. 5A, row c, B, C), as detected by immunocytochem-
istry and Western blot data. However, we did not find any
significant difference in expression of mitochondrial stress
response protein mortalin in all the treatment groups in
BV-2 microglial cells (Fig. 5B, C).
ASH-WEX and FIV has the inhibitory effect on the BV-2
microglial cells migration
Microglial cell migration is the hallmark of the inflam-
matory reactions, and chronic activation of the microglia
is reported in various neurodegenerative diseases. There-
fore, to determine the potential of the ASH-WEX and FIV
to inhibit the microglial migration, scratch assay was
performed using BV-2 microglial cells and migration into
the cell-free scratch area was documented. Representative
phase contrast images before and after treatment clearly
showed that ASH-WEX and FIV pretreatment to the
LPS-induced BV-2 microglial cells reduced their migration
to the scratched area (Fig. 6a). The gap size was reduced
to 36 % of the original gap size after 24 h (taking gap size
at 0 h as 100 %) in LPS-treated BV-2 microglia. However,
in ASH-WEX- and FIV-pretreated LPS-activated BV-2
microglia, gap size was 65 and 75 % of the original gap
size after 24 h, respectively, indicating anti-migratory po-
tential of the ASH-WEX and FIV (p ≤ 0.05; Fig. 6b).
ASH-WEX and FIV caused the cell cycle arrest and
apoptosis of the activated BV-2 microglial cells
Activated microglial cells generally undergo proliferation;
thus, we further studied whether ASH-WEX and FIV also
Fig. 4 ASH-WEX- and FIV-mediated prevention of oxidative stress induced due to neuroinflammation in primary microglia. A Represents the confocal
images of the (a) CellROX staining, (b) Mitotracker staining, and (c) HSP 70 immunostaining of the LPS-activated primary microglia with or
without pretreatment with ASH-WEX and FIV illustrating the decreased levels of the reactive oxygen species and prevention of the mitochondrial
turbulences induced due to the LPS treatment. B Histogram represents the relative optical intensity of HSP 70 in different treated groups as
compared to control. *p < 0.05 represents statistically significant difference between control and LPS + ASH-WEX and LPS + FIV-treated groups.
+p < 0.05 represents statistically significant difference between control and LPS-treated group. #p < 0.05 represents statistically significant
difference between LPS and LPS + ASH-WEX and LPS + FIV-treated groups
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arrest the cell cycle progression. The cell cycle distribution
data revealed that treatment of the BV-2 microglia with
LPS slightly increased their proliferation rate with 42.78 %
cells in Go/G1, 31.63 % in S, and 25.59 % in G2/M phases of
the cell cycle as compared to control cultures (44.55 % cells
in Go/G1, 27.02 % in S, and 28.43 % in G2/M phases)
(Fig. 7a, i–v). However, pretreatment of these cells with
ASH-WEX inhibited this LPS-induced proliferation (Go/G1
(45.15 %), S (28.02 %), and G2/M (26.83 %) phases). This
inhibition of proliferation was more pronounced in FIV-
pretreated group (Go/G1 (47.39 %), S (24.51 %), and G2/M
(28.10 %) phases). Consistent with these results, both
extracts were also seen to inhibit the expression of Cyclin
D1 which is required for the cell cycle progression (Fig. 7B,
i, ii). The expression of another cell cycle regulatory protein
PCNA, a DNA clamp loading protein, was also found to be
downregulated in ASH-WEX- and FIV-pretreated groups
(Fig. 7b, i, iii).
Further, to investigate whether ASH-WEX and FIV
also induce apoptosis/pro-apoptosis of the activated BV-
2 microglia, we performed the Annexin V-FITC assay.
Treatment of the BV-2 microglia with LPS showed
63.07 % live cells and 34.06 and 2.85 % cells in the early
and late apoptotic stage, respectively. Pretreatment of
these cells with ASH-WEX and FIV showed more cells
in apoptotic phase (39.48 % early apoptotic and 2.67 %
late apoptotic in case of ASH-WEX) and (45.17 % early
apoptotic and 2.72 % late apoptotic in FIV pretreatment
group) and less number of the live cells (57.84 % in
ASH-WEX and 52.12 % in FIV group) as compared to
the LPS-treated microglia (Fig. 8a, i–v). Moreover, LPS
treatment induced the expression of anti-apoptotic
Fig. 5 ASH-WEX and FIV prevent oxidative stress induced due to neuroinflammation in BV-2 microglial cells. A Represents the confocal images of the
(a) CellROX staining, (b) Mitotracker staining, and (c) HSP 70 immunostaining of the LPS-activated BV-2 microglia with or without pretreatment with
ASH-WEX and FIV illustrating the decreased levels of the reactive oxygen species and prevention of the mitochondrial turbulences induced due to the
LPS treatment. B Representative Western blots of HSP 70, mortalin showing elevated levels of HSP 70, mortalin levels with ASH-WEX and
FIV pretreatment. C Histogram presenting mean of densitometric analysis of Western blot signals of HSP 70, mortalin after normalization with α-tubulin
Gupta and Kaur Journal of Neuroinflammation  (2016) 13:193 Page 10 of 17
protein bcl-xl in BV-2 microglial cells, whereas ASH-
WEX and FIV pretreatments were observed to signifi-
cantly downregulate its expression (Fig. 8b, i, ii; p ≤ 0.05)
and upregulation of expression of apoptotic cascade pro-
tein PARP (Fig. 8b, i, iii). This data suggest that pretreat-
ment with ASH-WEX and FIV to LPS-activated BV-2
microglia may induce apoptosis of inflamed BV-2 micro-
glial cells.
Wit A and Withanone as the active components in
ASH-WEX and FIV
As ASH-WEX was seen to inhibit the microglial-mediated
neuroinflammation, the fractionation and characterization
of the ASH-WEX was performed to ascertain the bio-
active components. ASH-WEX was subjected to a series
of solvent extraction, and various soluble hexane, chloro-
form, ethylacetate, and butanol fractions were obtained
(Fig. 9a). They were then assessed for cytotoxicity assay
using BV-2 microglial cells. Out of the four fractions,
chloroform fraction was found to be more active than the
crude ASH-WEX. Later, chloroform fraction was further
fractionated using thin-layer chromatography (mobile
phase 97 hexane: 3 ethylacetate). Further, four fractions
were obtained and evaluated for the cytotoxicity. Out of
these, FIV was found to be the most active (Fig. 9b). Then,
ASH-WEX and FIV were subjected to HPLC analysis for
the possible bioactive molecules as compared to known
standards from Ashwagandha. Both the extracts were
found to contain Wit A and Withanone with more quan-
tity and in suitable proportion (approx 2:1 ratio of Wit A
and Withanone) in FIV.
Discussion
Suppression of microglial-mediated neuroinflammation is
considered as an important target in developing the thera-
peutics for the treatment of neurodegenerative diseases.
The current study was aimed to study the anti-
neuroinflammatory potential of the ASH-WEX and its ac-
tive chloroform fraction (FIV). MTT assay revealed that
treatment of the BV-2 microglial cells with ASH-WEX
and FIV for 48 h reduced their proliferation rate, since
ASH-WEX and FIV treatment decreased the cell viability
Fig. 6 ASH-WEX and FIV attenuate the migration of the LPS-activated BV-2 microglia. BV-2 microglial cells were grown as a confluent monolayer, injured
by applying a scratch and with ASH-WEX and FIV with and without treatment with LPS. a Representative phase contrast images which were taken at 0
and 24 h after scratching. b Histogram represents the percentage gap size after the 24 h (0 h gap was taken as 100 %). +p< 0.05 represents statistically
significant difference between control and LPS-treated group. #p< 0.05 represents statistically significant difference between LPS and LPS + ASH-WEX and
LPS + FIV-treated groups
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beyond the concentration ≥0.5 % and ≥15 μg/ml, respect-
ively, in dose dependent manner. So 0.2 % of ASH-WEX
and 10 μg/ml of FIV were chosen as the effective dose for
further experiments. BV-2 and primary microglia activated
with both 100 ng/ml of bacterial endotoxin LPS and 5 nm
of β-amyloid were used as in vitro model system for pre-
liminary experiments.
In the adult brain, microglia exhibit ramified morphology
and are involved in immune surveillance. In response to
the immunological insult, these quiescent microglial cells
retract their ramifications, transforming into an amoeboid-
like cells with motile protrusions responsible for its inflam-
matory phenotype [27]. α-Tubulin immunostaining and
phase contrast images showed that ASH-WEX and FIV
inhibited both LPS- and β-amyloid-induced amoeboid
morphology of these cells and restored their ramified
morphology. At the molecular level, ASH-WEX and
FIV pretreatment significantly suppressed the expression of
the microglial-specific marker Iba-1 which was upregulated
in both LPS- and β-amyloid-treated BV-2 and primary
microglial cells. Iba-1, 17 kDa calcium-binding adaptor pro-
tein, has been reported to be upregulated during inflamma-
tion which helps to discriminate between the surveilling
and activated microglia [28, 29]. These observations pro-
vided the first line of evidence that ASH-WEX and FIV
inhibited LPS- and β-amyloid-induced microglial activation
xand suppressed neuroinflammation. Further, ASH-WEX-
and FIV-pretreated BV-2 microglial cells also showed the
downregulated expression of the MHC II compared to
LPS-treated BV-2 microglial cells as detected by OX-6
immunostaining.
LPS-induced activation of both primary and BV-2
microglial cells was seen to increase the production of
ROS (as detected by CellROX staining) which was associ-
ated with higher mitochondrial activity as evident from in-
creased fluorescence of Green FM dye. The mitochondrial
dysfunction plays important role in the ROS production in
various models of chronic inflammation [30, 31]. LPS-
treated primary and BV-2 microglial cells also showed
higher level of nitrite released in the media which is already
reported to cause upregulation of iNOS and results in the
synthesis of high levels of NO [32]. Interestingly, pretreat-
ment with ASH-WEX and FIV suppressed the effects of
LPS as both ASH-WEX and FIV were observed to inhibit
production of ROS and nitrite, thus resulting in reduced
mitochondrial stress. It may be suggested that both extracts
may prevent the oxidative damage during neuroinflamma-
tion by regulating the mitochondrial homeostasis. Various
previous studies also reported anti-oxidative potential of
Withania leaf extract in physiological abnormalities seen in
the PD [33]. These observations are also supported by the
upregulated expression of the mitochondrial stress response
Fig. 7 ASH-WEX and FIV suppresses proliferation of activated BV-2 microglial cells by causing cell cycle arrest. A i–v Represents plots showing the
cell cycle analysis of the ASH-WEX- and FIV-treated BV-2 microglia with or without activation with LPS analyzed by PI stain using flow cytometer,
and histogram presents the distribution of cells in G0/G1, S, and G2/M phases of cell cycle. B i Representative Western blot of Cyclin D1 and PCNA
showing decrease in expression of Cyclin D1 and PCNA on ASH-WEX and FIV treatment. B ii, iii Histograms presenting mean of densitometric analysis
of Western blot signals of Cyclin D1 and PCNA after normalization with α-tubulin. The data were obtained from three independent experiments
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proteins like HSP 70 and mortalin in the ASH-WEX- and
FIV-pretreated LPS-activated microglia. The overexpression
of these chaperone proteins are known to protect the mito-
chondria and reduce oxidative stress [34, 35]. Upregulation
of HSP 70 is also reported to suppress LPS-induced cyto-
kine expressions by inhibiting the IkBα degradation and
NFkB nuclear translocation [36]. Shikonin is reported to at-
tenuate the production of NO/iNOS, TNF-α, IL-1β, and
COX-2 in LPS-stimulated microglia by inhibiting Akt phos-
phorylation [37].
Enhanced production of ROS amplifies the inflammatory
reaction and contributes to the subsequent neuronal dam-
age in neurodegenerative diseases. This was evident from
the sandwich ELISA-based immunoassay data showing dra-
matic increase in TNF-α, IL-1β, and IL-6 production in
LPS-treated microglial cells. This increase in the release of
these cytokines was significantly inhibited by ASH-WEX
and FIV pretreatment to these LPS-treated cells. Experi-
ments carried out in vitro and in vivo have demonstrated
that TNF-α promotes neurodegeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNpc) in
PD [38]. Experiments using different mutant mice deficient
in iNOS or TNFα receptors have shown reduced neurotox-
icity [39, 40]. A recent study reported that LPS activates the
microglia with immediate superoxide release and later en-
hances the production of TNF-α, NO, prostaglandin E2
(PGE2), and IL-1β [41]. The current data may suggest that
ASH-WEX and FIV inhibited microglial-mediated neuroin-
flammation by preventing the release of the ROS, RNS, and
pro-inflammatory cytokines which work synergistically to
induce the neurotoxicity and increase the duration of the
chronic inflammation [42]. Wit A also has been reported to
inhibit the iNOS expression and NO production in Raw
264.7 cells [43].
Fig. 8 ASH-WEX and FIV induce the apoptosis of the LPS-activated BV-2 microglia. A, i–vii Represents the Annexin-FITC assay of the ASH-WEX- and
FIV-treated BV-2 microglia with or without activation with LPS using flow cytometer. B i Representative Western blots of Bcl-xl and PARP showing
decrease in expression of Bcl-xl and corresponding increase in the level of PARP release on ASH-WEX and FIV treatment. B, ii, iii Histograms presenting
mean of densitometric analysis of Western blot signals of Bcl-xl and PARP after normalization with α-tubulin. The data were obtained from
three independent experiments. +p < 0.05 represents statistically significant difference between control and LPS-treated group. #p < 0.05 represents
statistically significant difference between LPS and LPS + ASH-WEX and LPS + FIV-treated groups
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LPS-induced inflammatory cascades in microglial cells
include activation of pathways such as NFkB, MAPK,
and PI3K-Akt pathways, which have high implication in
neurodegenerative processes [23]. Downregulated ex-
pression of the transcription factor NFkB in the ASH-
WEX- and FIV-pretreated cells was also accompanied by
inhibition of its translocation from cytoplasm to nuclear
compartment. NFkB activation and its translocation are
critical for the expression of the various cytokines, che-
mokines, receptors required for neutrophil adhesion and
migration, MHCs, iNOS, and COX-2 in microglia in re-
sponse to LPS [44, 45]. Our results are in line with the
recent reports suggesting that anti-inflammatory activity
of 30 % methanolic extract of the Withania leaves in
stainless steel implant induced inflammation in zebrafish
by inhibiting the NFkB transcriptional activity [46].
Further, its active component, i.e., Wit A has also been
reported to inhibit the NFkB activity in cellular model of
cystic fibrosis inflammation [47].
ASH-WEX and FIV pretreatment to these microglial
cells also inhibited LPS-induced AP1 expression. The
transcriptional activation of the AP1 via JNK/MAPK
pathway has been reported to induce the production of
the pro-inflammatory factors in LPS-activated microglia
[48, 49]. The concerted action of both AP1 and NFkB
signaling pathways together results in the induction of
pro-inflammatory cytokines [50, 51]. Therefore, simul-
taneous inhibition of both NFkB and AP1 transcriptional
activity by ASH-WEX and FIV may be responsible for
their anti-neuroinflammatory potential of ASH-WEX and
FIV. Many other plant products like brevicompanine, cur-
cumin, and isooreintin have been reported to attenuate
the LPS-induced production of the inflammatory media-
tors through inhibiting both NFkB and AP1 pathways
Crude ASH-WEX
IC50: BV-2(1.5%(525ug/ml) but cell 
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Fig. 9 Bioactivity of the different fractions extracted from ASH-WEX and their characterization for the presence of active phytochemicals. a Flowchart
representing the IC50 of the different fractions extracted from ASH-WEX. b Line graphs represent the cytotoxicity assay of the BV-2 microglia treated
with different fractions after 48 h of the treatment. c HPLC chromatograms representing the presence of the bioactive components Withaferin A and
Withanone in the ASH-WEX and FIV.*p < 0.05 represents statistically significant difference between control and treated groups. d Table representing
the quantities of Withaferin A and Withanone in ASH-WEX and FIV and their biochemical structures
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[52–54]. Further, ASH-WEX- and FIV-pretreated cells
also showed significant downregulation in the expression
of p-AktSER473 as compared to LPS alone treated group.
Phosphorylation of Akt leads to changes in the catalytic
activity of downstream targets, such as GSK-3, mTOR,
COX-2, and mPGES-1, and results in secretion of various
prostaglandins and leukotrienes having inflammatory
activity [55–57].
During any insult to the brain or injury, the activation
of microglia leads to induction of proliferation and mi-
gration of these cells towards the site of the lesion with
elevated production of the various inflammatory mole-
cules [58, 59]. ASH-WEX and FIV pretreatment was
observed to downregulate the expression of the cell cycle
regulatory proteins PCNA and Cyclin D1 along with cell
cycle arrest of the LPS-activated BV-2 microglia at G0/G1
and G2/M phase. The inhibition of proliferation was also
accompanied by induction of apoptosis as depicted by
AnnexinV-FITC flow cytometry data. ASH-WEX- and FIV-
mediated induction of apoptosis may be the result of inhib-
ition of anti-apoptotic protein Bcl-xl. Upregulated Bcl-xl
expression has been detected in reactive microglia of the
patient with neurodegenerative diseases [60]. Both the
extracts were also seen to elevate the levels of the PARP
expression, whose cleavage into 27 and 87 kDa frag-
ments leads to the apoptosis progression. Apoptosis of
the inflamed microglial cells is one of the mechanisms
of the anti-inflammatory compounds to inhibit the neu-
roinflammation [61].
Further, ASH-WEX and FIV also inhibited the produc-
tion of the MMP 2 and MMP 9 suggesting their role in
maintaining the blood-brain barrier (BBB) integrity as
illustrated by gelatin zymogram data. MMPs are micro-
glial inflammatory factors that degrade components of
the basal lamina, leading to the disruption of the BBB,
and contribute to the neuroinflammatory response in
many neurological diseases [62]. Further released proteases
from activated microglia result in proteolytic degradation of
the BBB which further enhances the recruitment of the
microglia to the lesion site [63], as depicted by maximum
migration of cells to the scratched area in LPS-treated cul-
tures. ASH-WEX and FIV were observed to reduce rate of
Fig. 10 Graphical representation of the possible inflammatory cascades or proteins involved in the anti-neuroinflammatory potential of the
ASH-WEX and FIV
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migration of cells in scratched area which may also be due
to collective effect of the controlled proliferation, apoptosis,
and cell cycle arrest by the ASH-WEX and FIV pretreat-
ment. Based on these observations, it may be suggested that
ASH-WEX and especially FIV may prove to be potential
agent for preventing the uncontrolled migration of the
microglia to the lesion site during CNS injury.
Conclusions
In the light of the present study, it may be concluded that
ASH-WEX and one of its active chloroform fraction (FIV)
prevents the microglial-mediated neuroinflammation by
inhibiting the production of various pro-inflammatory
mediators via various inflammatory pathways (Fig. 10).
They also control the microglia proliferation and migra-
tion and led cells to undergo apoptosis. Furthermore, FIV
was more potent anti-inflammatory agent than the
crude ASH-WEX. We have also characterized the
ASH-WEX and its active chloroform fraction (FIV) for
the presence of bioactive components using the reverse
phase HPLC method. Interestingly, both extracts were
found to contain Wit A and Withanone, but FIV seems to
contain more quantity of Wit A and Withanone in suitable
proportion than ASH-WEX (Fig. 9). This may explain the
higher effectiveness of the FIV than the ASH-WEX in the
current results. The anti-neuroinflammatory activity of
the ASH-WEX and FIV might be due to the combin-
ation of Withanone and Wit A as active components.
In view of the current findings, the extract from this
plant may prove to provide safe and effective alternative
to the conventional NSAIDs used for the treatment of
the neurodegenerative diseases.
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